Legal Representation
Attorney
Bingham B. Leverich, Esq.
USPTO Deadlines
Application History
25 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Oct 16, 2008 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
| Oct 16, 2008 | MAB6 | O | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | Loading... |
| Jan 30, 2008 | EX4G | S | SOU EXTENSION 4 GRANTED | Loading... |
| Jan 7, 2008 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Jan 7, 2008 | EXT4 | S | SOU EXTENSION 4 FILED | Loading... |
| Sep 15, 2007 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
| Aug 1, 2007 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Aug 1, 2007 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
| Feb 14, 2007 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Feb 14, 2007 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| Feb 14, 2007 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| May 24, 2006 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| May 24, 2006 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| May 24, 2006 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Apr 12, 2006 | ASGN | I | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | Loading... |
| Feb 14, 2006 | NOAM | O | NOA MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Feb 3, 2006 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| Feb 3, 2006 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| Nov 22, 2005 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Nov 2, 2005 | NPUB | O | NOTICE OF PUBLICATION | Loading... |
| Sep 29, 2005 | PREV | O | LAW OFFICE PUBLICATION REVIEW COMPLETED | Loading... |
| Sep 23, 2005 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Sep 22, 2005 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Sep 19, 2005 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Mar 4, 2005 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations for use in the treatment of cholesterol reduction and cardiovascular diseases
First Use Anywhere:
0
First Use in Commerce:
0
Classification
International Classes
005